Bispecific monoclonal antibody 2B1

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBispecific monoclonal antibody 2B1

Drug Alias Name2B1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionNatural killer cells stimulantsMacrophages stimulantsLymphocytes stimulants

TargetsLow affinity immunoglobulin gamma Fc region receptor IIIReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesChiron Spa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChiron

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A